Literature DB >> 2182599

Immunobiology of chronic lymphocytic leukemia.

A S Freedman1.   

Abstract

The majority of CLLs are of B lineage derivation with about 5 per cent of cases of T lineage. Although morphologically resembling the small peripheral blood B cell, by virtue of the expression of B cell restricted and associated cell surface antigens, B-CLLs are not the neoplastic counterparts of normal resting B cells. Similar to the peripheral blood B cell, B-CLLs express CD19, CD20, CD21, CD24, CD40, CD44, CD45R, and sIgM/D. However, unlike peripheral blood B cells, B-CLLs generally do not express C3b complement receptor, LFA-1, or CD22. In addition, B-CLLs express the T cell associated antigen CD5, and a number of antigens induced on normal B cells following in vitro activation (B5, Blast-1, CD23). These findings support the hypothesis that B-CLLs are the neoplastic counterparts of one or more unique subpopulations of normal B cells. Normal CD5+ B cells, which phenotypically resemble B-CLL, are present in fetal lymphoid tissues and in small numbers in adults. Moreover, normal CD5+ B cells are present in increased numbers in patients with autoimmune diseases and a subset of normal in vitro activated B cells phenotypically resemble B-CLL. Similar studies into the state of differentiation of T-CLL cells suggest that although most cases resemble normal activated T helper cells, a significant number are the neoplastic counterparts of natural killer cells. Recent studies have examined the function of B and T cells in B-CLL. Although controversial, these studies suggest that the in vitro response to mitogens and cytokines of B-CLL cells is abnormal. T cell proliferation in B-CLL is depressed due to an inability to produce sufficient T cell growth factor (IL-2) as well as a poor response to exogenous IL-2 possibly from ineffective IL-2 receptor expression. Purified populations of T helper and T suppressor cells demonstrate insufficient support of Ig production by normal B cells as well as excess suppression, respectively. These studies have further supported the previous hypothesis that the depressed cellular and humoral immunity in CLL is multifactorial with both abnormal B and T cell function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182599

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Comparison of protein synthesis profiles in chronic lymphocytic leukaemia cells and B-lymphocytes from peripheral blood, cord blood and tonsil.

Authors:  F K Saunders; J Lawry; D A Winfield; J R Goepel; B W Hancock; R M Sharrard; M H Goyns
Journal:  Experientia       Date:  1994-05-15

2.  Acute renal failure with chronic lymphocytic leukaemia.

Authors:  A Martinez-Vea; M J Herranz; A Llorente; M Carrera; C García; S Razquín; J A Oliver
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

3.  Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia.

Authors:  S J Hill; S H Peters; M J Ayliffe; J Merceica; A S Bansal
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  Cytokine Release Ensuing Interaction Between Human Peripheral Blood Mononuclears and Epstein-Barr Virus Transformed B-CLL Cell Line.

Authors:  Hanna Bessler; Chiya Moshe Leibovitch; Meir Djaldetti
Journal:  J Immunother Precis Oncol       Date:  2020-04-28

5.  Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes.

Authors:  A M Walker; D W Montgomery; S Saraiya; T W Ho; H S Garewal; J Wilson; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.